- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Wockhardt's quarterly financial results show revenue at INR 738 Cr with EBITDA up 1% to INR 101 Cr. A major strategic shift involves exiting the US generics business, incurring a one-time charge of (97) Cr to eliminate recurring losses and sharpen focus on innovation-led growth. This resulted in a net loss of (108) Cr. The company significantly advanced its novel antibiotic pipeline: Zaynich is filed in India with US FDA NDA planned shortly. Miqnaf recently launched in India, receiving encouraging initial clinician response. Regional businesses showed strong growth: India up 8% to Rs. 178 Cr, UK up 13% to Rs. 312 Cr, and Ireland up 11% to Rs. 50 Cr.